Millipore Sigma Vibrant Logo

420104 JAK3 Inhibitor II - CAS 211555-04-3 - Calbiochem

The JAK3 Inhibitor II, also referenced under CAS 211555-04-3, controls the biological activity of JAK3. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: 4-[(3ʹ-Bromo-4ʹ-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, WHI-P154

Primary Target: JAK-3
View Products on Sigmaaldrich.com
420104
Preis & Verfügbarkeit

Übersicht

Replacement Information

Key Spec Table

CAS #Empirical Formula
211555-04-3C₁₆H₁₄BrN₃O₃

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
420104-5MG
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Kst.-Ampulle 5 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      OverviewA potent, cell-permeable, reversible, ATP-competitive, and specific inhibitor of JAK3 (IC50 = 5.6 µM). Has no effect on either JAK1 or JAK2. Has also been shown to prevent the ionizing radiation-induced activation of c-Jun in DT-40 cells. Also acts as a potent inhibitor of glioblastoma cell adhesion and migration.
      Catalogue Number420104
      Brand Family Calbiochem®
      Synonyms4-[(3ʹ-Bromo-4ʹ-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, WHI-P154
      References
      ReferencesGhosh, S., et al. 2001. Acta Crystallogr. C. 57, 76.
      Sudbeck, E.A., et al. 1999. Clin. Cancer Res. 5, 1569.
      Goodman, P.A., et al. 1998. J. Biol. Chem. 273, 17742.
      Narla, R.K., et al. 1998. Clin Cancer Res. 4, 2463.
      Product Information
      CAS number211555-04-3
      ATP CompetitiveY
      FormPale yellow solid
      Hill FormulaC₁₆H₁₄BrN₃O₃
      Chemical formulaC₁₆H₁₄BrN₃O₃
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetJAK-3
      Primary Target IC<sub>50</sub>5.6 µM against JAK3
      Purity≥97% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      420104-5MG 04055977187908

      Documentation

      JAK3 Inhibitor II - CAS 211555-04-3 - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      JAK3 Inhibitor II - CAS 211555-04-3 - Calbiochem Analysenzertifikate

      TitelChargennummer
      420104

      Literatur

      Übersicht
      Ghosh, S., et al. 2001. Acta Crystallogr. C. 57, 76.
      Sudbeck, E.A., et al. 1999. Clin. Cancer Res. 5, 1569.
      Goodman, P.A., et al. 1998. J. Biol. Chem. 273, 17742.
      Narla, R.K., et al. 1998. Clin Cancer Res. 4, 2463.

      Technische Informationen

      Titel
      JAK/STAT Signaling Research Focus
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision12-January-2010 RFH
      Synonyms4-[(3ʹ-Bromo-4ʹ-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, WHI-P154
      DescriptionA potent, cell-permeable, reversible, ATP-competitive, and specific inhibitor of JAK3. Has no effect on either JAK1 or JAK2. Has also been shown to prevent the ionizing radiation-induced activation of c-jun in DT-40 cells.
      FormPale yellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number211555-04-3
      Chemical formulaC₁₆H₁₄BrN₃O₃
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesGhosh, S., et al. 2001. Acta Crystallogr. C. 57, 76.
      Sudbeck, E.A., et al. 1999. Clin. Cancer Res. 5, 1569.
      Goodman, P.A., et al. 1998. J. Biol. Chem. 273, 17742.
      Narla, R.K., et al. 1998. Clin Cancer Res. 4, 2463.